Filling Tresiba® prescriptions: What you need to know

Tresiba® is a once-daily, long-acting insulin indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.1 Tresiba® comes in 3 administration options: Tresiba® FlexTouch® U-100, Tresiba® FlexTouch® U-200, and a U-100 multiple-dose, 10-mL vial.1

Savings information ▾

Tresiba® facts ▾

FlexTouch® U-100 box
Concentration

100 units/mL

Pens per package

5

Volume per pen

3 mL

Units of insulin per pen

300 units

Units of insulin per package

1500 units

Max dose per injection

80 units

Dose increment

1 unit

NDC number

0169-2660-15


Don’t forget to order NovoFine® Plus disposable needles. The 32G, 4-mm pen needle is Novo Nordisk's shortest and thinnest needle available.a

aNeedles are sold separately and may require a prescription in some states.

FlexTouch® U-200 box
Concentration

200 units/mL

Pens per package

3

Volume per pen

3 mL

Units of insulin per pen

600 units

Units of insulin per package

1800 units

Max dose per injection

160 units

Dose increment

2 units

NDC number

0169-2550-13


Don’t forget to order NovoFine® Plus disposable needles. The 32G, 4-mm pen needle is Novo Nordisk's shortest and thinnest needle available.a

aNeedles are sold separately and may require a prescription in some states.

Tresiba® 10 mL vial
Concentration

100 units/mL

Vials per package

1 vial

Volume per vial

10 mL

Units of insulin per vial

1000 units

NDC number

0169-2662-11


An option for patients who prefer vials or children who require fewer than 5 units a day.

Click below to see more information about each administration option.

Tresiba® FlexTouch® U‑100

FlexTouch® U-100 box
Concentration

100 units/mL

Pens per package

5

Volume per pen

3 mL

Units of insulin per pen

300 units

Units of insulin per package

1500 units

Max dose per injection

80 units

Dose increment

1 unit

NDC number

0169-2660-15


Don’t forget to order NovoFine® Plus disposable needles. The 32G, 4-mm pen needle is Novo Nordisk's shortest and thinnest needle available.a

aNeedles are sold separately and may require a prescription in some states.

Tresiba® FlexTouch® U‑200

FlexTouch® U-200 box
Concentration

200 units/mL

Pens per package

3

Volume per pen

3 mL

Units of insulin per pen

600 units

Units of insulin per package

1800 units

Max dose per injection

160 units

Dose increment

2 units

NDC number

0169-2550-13


Don’t forget to order NovoFine® Plus disposable needles. The 32G, 4-mm pen needle is Novo Nordisk's shortest and thinnest needle available.a

aNeedles are sold separately and may require a prescription in some states.

U-100 multiple-dose, 10-mL vial

Tresiba® 10 mL vial
Concentration

100 units/mL

Vials per package

1 vial

Volume per vial

10 mL

Units of insulin per vial

1000 units

NDC number

0169-2662-11


An option for patients who prefer vials or children who require fewer than 5 units a day.

Download the Insulin Portfolio Pharmacy Reference Guide ▾

Patient Savings Card

Eligible patients pay as little as as $25 or no more than $99 per prescriptionb

See savings

bEligibility and other restrictions apply.

Other facts about Tresiba®1:

Injected subcutaneously once daily, and for adults, at any time of day

  • Instruct adult patients who miss a dose of Tresiba® to inject their daily dose during waking hours upon discovering the missed dose, then continue with their regular dosing schedule
  • Tresiba® must be dosed at the same time each day for pediatric patients. Instruct pediatric patients who miss a dose of Tresiba® to contact their health care provider for guidance and to monitor blood glucose levels more frequently until the next scheduled dose
  • Instruct adult patients to ensure that at least 8 hours have elapsed between consecutive Tresiba® injections

The recommended time between dose increases is 3 to 4 days

  • No dose conversion needed

Opened (in-use) Tresiba® can be kept at room temperature (below 86°F), away from direct heat and light, or refrigerated (36°F to 46°F) for 56 days (8 weeks)

  • The dose window for the Tresiba® FlexTouch® U-100 and U-200 pens shows the number of units to be delivered
  • The vial offers an option for patients who prefer vials or children who require fewer than 5 units a day 
primary_msg

Give your patients a game plan with the Diabetes Health Coach

Cornerstones4Care® with blue grey letters

Hand phone icon

Live calls from a Certified Diabetes Educator for the first 90 days of therapy for patients with diabetes starting Tresiba®, available in both English and Spanish.c


Blue computer icon

Personalized online coaching sessions on more than 25 topics—developed by leading diabetes experts.


Blue phone and envelope

Ongoing support that includes tools, education, interactive trackers, and diabetes-friendly recipes.

secondary_msg

Encourage patients taking Tresiba® to register for personalized support.

Go to Tresiba.com

cPatients with diabetes qualify for live phone support if they have been taking Tresiba® for less than 6 months and requested calls when registering for Cornerstones4Care®.

View coverage for your patients on Medicare Part D

Check coverage

Selected Important Safety Information

Contraindications

  • Tresiba® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to Tresiba® or one of its excipients

Warnings and Precautions

  • Never Share a Tresiba® FlexTouch® Pen, Needle, or Syringe Between Patients, even if the needle is changed. Patients using Tresiba® vials should never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens
  • Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Changes in an insulin regimen (e.g., insulin strength, manufacturer, type, or injection site or method of administration) may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis have been reported to result in hyperglycemia; and a sudden change in the injection site (to an unaffected area) has been reported to result in hypoglycemia. Make any changes to a patient’s insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. Advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor for hypoglycemia. Adjustments in concomitant anti-diabetic treatment may be needed.
  • Hypoglycemia is the most common adverse reaction of insulin, including Tresiba®, and may be life-threatening

Indications and Usage

Tresiba® (insulin degludec injection) is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.

Limitations of Use

Tresiba® is not recommended for treating diabetic ketoacidosis.

Important Safety Information

Contraindications

  • Tresiba® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to Tresiba® or one of its excipients

Warnings and Precautions

  • Never Share a Tresiba® FlexTouch® Pen, Needle, or Syringe Between Patients, even if the needle is changed. Patients using Tresiba® vials should never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens
  • Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Changes in an insulin regimen (e.g., insulin strength, manufacturer, type, or injection site or method of administration) may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis have been reported to result in hyperglycemia; and a sudden change in the injection site (to an unaffected area) has been reported to result in hypoglycemia. Make any changes to a patient’s insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. Advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor for hypoglycemia. Adjustments in concomitant anti-diabetic treatment may be needed.
  • Hypoglycemia is the most common adverse reaction of insulin, including Tresiba®, and may be life-threatening. Increase monitoring with changes to: insulin dose, co-administered glucose lowering medications, meal pattern, physical activity; and in patients with hypoglycemia unawareness or renal or hepatic impairment
  • Accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. To avoid medication errors, always instruct patients to check the insulin label before each injection
  • Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including Tresiba®
  • As with all insulins, Tresiba® use can lead to life-threatening hypokalemia, which then may cause respiratory paralysis, ventricular arrhythmia, and death. Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated
  • Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including Tresiba®. Patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of the TZD must be considered

Adverse Reactions

  • Adverse reactions commonly associated with Tresiba® are hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema, and weight gain

Drug Interactions

  • There are certain drugs that may cause clinically significant drug interactions with Tresiba®.
    • Drugs that may increase the risk of hypoglycemia: antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors
    • Drugs that may decrease the blood glucose lowering effect: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones
    • Drugs that may increase or decrease the blood glucose lowering effect: alcohol, beta-blockers, clonidine, lithium salts, and pentamidine
    • Drugs that may blunt the signs and symptoms of hypoglycemia: beta-blockers, clonidine, guanethidine, and reserpine

Please click here for Prescribing Information

 

 

Reference:

  1. Tresiba [package insert]. Plainsboro, NJ: Novo Nordisk Inc; November 2019.